Seeking Alpha

More on Myriad Genetics (MYGN): FQ3 beats across the board on a 12% Y/Y increase in revenue....

More on Myriad Genetics (MYGN): FQ3 beats across the board on a 12% Y/Y increase in revenue. Molecular diagnostic testing revenue rose +20% over the prior year, while revenue from its BRACAnalysis test, which represented 74% of total revenue, grew by 9%. Operating income +26%, while operating margin rose to 37% from 35.5%. Shares +2.5% AH.
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Tools
Find the right ETFs for your portfolio:
Seeking Alpha's new ETF Hub
ETF Investment Guide:
Table of Contents | One Page Summary
Read about different ETF Asset Classes:
ETF Selector

Next headline on your portfolio:

|